The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.
O Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.
Angiotensin Receptor Antagonists
/ metabolism
Angiotensin-Converting Enzyme 2
Animals
Antirheumatic Agents
/ therapeutic use
Antiviral Agents
/ therapeutic use
Betacoronavirus
COVID-19
Cardiovascular Diseases
/ enzymology
China
/ epidemiology
Chloroquine
/ therapeutic use
Comorbidity
Coronavirus Infections
/ drug therapy
Humans
Hypertension
/ enzymology
Pandemics
Peptidyl-Dipeptidase A
/ metabolism
Pneumonia, Viral
/ drug therapy
SARS-CoV-2
Journal
Arquivos brasileiros de cardiologia
ISSN: 1678-4170
Titre abrégé: Arq Bras Cardiol
Pays: Brazil
ID NLM: 0421031
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
02
04
2020
accepted:
08
04
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
10
6
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19. A doença de coronavírus 2019 (COVID-19) é uma pandemia global afetando o mundo, estando presente em mais de 1.300.000 pacientes. O COVID-19 age pelo receptor da enzima conversora de angiotensina 2 (ECA2). As comorbidades cardiovasculares são mais frequentes com COVID-19, e cerca 10% de casos desenvolvem miocardite (22% de pacientes críticas). Mais pesquisas serão necessárias para continuar ou descontinuar inibidores de ECA e bloqueadores dos receptores da angiotensina, que são essenciais para hipertensão e insuficiência cardíaca em COVID-19. Pesquisa intensiva é promissora para o tratamento e a prevenção da COVID-19.
Autres résumés
Type: Publisher
(por)
A doença de coronavírus 2019 (COVID-19) é uma pandemia global afetando o mundo, estando presente em mais de 1.300.000 pacientes. O COVID-19 age pelo receptor da enzima conversora de angiotensina 2 (ECA2). As comorbidades cardiovasculares são mais frequentes com COVID-19, e cerca 10% de casos desenvolvem miocardite (22% de pacientes críticas). Mais pesquisas serão necessárias para continuar ou descontinuar inibidores de ECA e bloqueadores dos receptores da angiotensina, que são essenciais para hipertensão e insuficiência cardíaca em COVID-19. Pesquisa intensiva é promissora para o tratamento e a prevenção da COVID-19.
Identifiants
pubmed: 32491073
pii: S0066-782X2020000600817
doi: 10.36660/abc.20200273
pmc: PMC8386999
pii:
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Antirheumatic Agents
0
Antiviral Agents
0
Chloroquine
886U3H6UFF
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Review
Langues
eng
por
Sous-ensembles de citation
IM
Pagination
817-822Références
JAMA Cardiol. 2020 Jul 1;5(7):819-824
pubmed: 32219357
J Travel Med. 2020 May 18;27(3):
pubmed: 32186711
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):567-571
pubmed: 32141280
Clin Pharmacokinet. 2018 Oct;57(10):1347-1354
pubmed: 29453687
Life Sci. 2020 May 1;248:117477
pubmed: 32119961
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
Eur J Clin Invest. 2009 Jul;39(7):618-25
pubmed: 19453650
Zhonghua Wai Ke Za Zhi. 2020 Mar 1;58(3):178-182
pubmed: 32187921
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jun 24;48(6):450-455
pubmed: 32120458
Eur Heart J. 2021 Jan 7;42(2):206
pubmed: 32176300
Thorax. 2003 Aug;58(8):686-9
pubmed: 12885985
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Infection. 2020 Oct;48(5):773-777
pubmed: 32277408
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Clin Pharmacol Ther. 2019 Jan;105(1):219-228
pubmed: 29696643
Curr Biol. 2020 Apr 20;30(8):1578
pubmed: 32315626
JAMA. 2003 Jun 4;289(21):2801-9
pubmed: 12734147
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Antiviral Res. 2020 May;177:104762
pubmed: 32147496
Europace. 2017 Aug 01;19(8):1280-1287
pubmed: 27738071
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Ann Pharmacother. 2016 Nov;50(11):909-917
pubmed: 27465881
Lancet Respir Med. 2020 May;8(5):e30-e31
pubmed: 32222166
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Circulation. 2017 Nov 14;136(20):1955-1975
pubmed: 29084738
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Br J Clin Pharmacol. 2013 Sep;76(3):455-66
pubmed: 23305158
Int J Pept. 2012;2012:256294
pubmed: 22536270
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Int J Infect Dis. 2016 Aug;49:129-33
pubmed: 27352628
J Cell Mol Med. 2015 Aug;19(8):1965-74
pubmed: 25766467
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Immunopharmacol Immunotoxicol. 2013 Jun;35(3):434-42
pubmed: 23635029
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Br J Clin Pharmacol. 2015 May;79(5):838-46
pubmed: 25377242
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904